Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis-Reference-Cited by-同舟云学术

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Published:2015-04-10 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Martí-Carvajal Arturo J¹,Anand Vidhu²,Solà Ivan³

Affiliation:

1. Iberoamerican Cochrane Network; Valencia Venezuela

2. University of Minnesota; Department of Medicine; 420 Delaware Street SE Mayo Mail Code 195 Minneapolis MN USA 55455

3. CIBER Epidemiología y Salud Pública (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 - Edifici Casa de Convalescència Barcelona Catalunya Spain 08041

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD010298.pub2/fullpdf

Reference175 articles.

1. Mesa R Verstovsek S Gupta V Mascarenhas J Atallah E Sun W Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I Blood (ASH Annual Meeting Abstracts) 2012

2. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial;Mesa;Journal of Clinical Oncology,2013

3. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial;Mesa;Cancer,2011

4. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study;Mesa;Leukemia Research,2013

5. Talpaz M Paquette R Afrin L Hamburg S Jamieson K Terebelo H Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 10 9 /L): a comparison to patients with normal or high starting platelet counts Blood (ASH Annual Meeting Abstracts) 2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methodological challenges in the development of endpoints for myelofibrosis clinical trials;The Lancet Haematology;2024-05

2. Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients;Bone Marrow Transplantation;2024-04-05

3. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study;Bone Marrow Transplantation;2023-11-08

4. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia;British Journal of Haematology;2023-09-19

5. Emerging Treatment Options for Myelofibrosis: Focus on Anemia;Therapeutics and Clinical Risk Management;2023-06